Lawmakers and Experts Will Discuss Solutions to Hold Big Pharma Accountable for Anti-Competitive Tactics That Keep Drug Prices High Washington, D.C. – On Tuesday, February 6 at 10:00 AM, Campaign for Sustainable Rx Pricing (CSRxP) executive director Lauren Aronson will participate in a panel discussion with U.S. Senators Peter Welch (D-VT) and Amy Klobuchar (D-MN) on […]
Big Pharma Giant Kicks Off Q4 Earnings After Hiking Prices More Than 40 Times in 2023 This past week, brand name drug giant Johnson & Johnson kicked off the first round of Big Pharma earnings calls for the fourth quarter of 2023. The company surpassed Wall Street analysts’ earnings and profit expectations after hiking prices […]
Big Pharma Price Hikes, Rising Launch Prices And Patent Abuse Impose Massive Costs on Patients, Taxpayers, and the U.S. Health Care System Tomorrow, the U.S. House Committee on Energy and Commerce Health Subcommittee is scheduled to hold a hearing to discuss health care spending in the United States. Ahead of the hearing on this important topic, get […]
Rx Price Watch Analysis Finds Big Pharma Price Increases Outpaced Inflation Every Year Except One Between 2006 and 2020 A new report from AARP finds Big Pharma “consistently” increased prices above the rate of inflation between 2006 and 2020. In fact, the report found that Big Pharma increased prices on 943 blockbuster drugs widely used […]
Brand Name Drug Companies’ Price Increases in First Two Weeks of 2024 Continue to Outpace the Rate of Inflation Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Thursday on a new report that found Big Pharma hiked prices on 775 brand name prescription drugs in the first two weeks of the […]
Report Finds Several Brand Name Drug Companies Waiting to Introduce New Products Until They Can Get Approval for More Lucrative Disease Classes It appears egregious price hikes on existing prescription drugs, out-of-control prices on new products and anti-competitive schemes to extend monopolies just aren’t enough to satisfy Big Pharma’s appetite for putting profits over patients. […]
Big Pharma Giant Switches Popular Brand Name Inhaler to Authorized Generic to Maintain Monopoly Pricing Power and End-Run Solutions Meant to Discourage Price Increases Above the Rate of Inflation Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Friday on GSK’s strategy to discontinue the brand name inhaler Flovent and replace the product […]
Report Finds Big Pharma Increased Spending on R&D in First Half of 2023, Made R&D Investment Decisions Without Considering Impact of 2022 Drug Pricing Solutions A recent analysis from research firm ATI Advisory shows that in the first half of 2023, Big Pharma’s research and development (R&D) investment decisions were not impacted by drug pricing […]
Big Pharma Maintains Business-as-Usual Approach to Price-Gouging Americans to Start the New Year Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today on reports that brand name drug companies plan to hike prices on at least 500 prescription drugs to start the year, as part of the pharmaceutical industry’s traditional biennial […]
Big Pharma Discredited Its Own Bogus Rhetoric on Research and Development in 2023 With each new year comes a time-honored tradition for Big Pharma: Hiking prices on hundreds of brand name prescription drugs in the first two weeks of January. As Big Pharma’s next round of January price hikes approach, we can take a look […]